OncoMatch/Clinical Trials/NCT06824701
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Is NCT06824701 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Tazemetostat and Zanubrutinib for relapsed or refractory b-cell non-hodgkin lymphoma.
Treatment: Tazemetostat · Zanubrutinib · Rituximab · Obinutuzumab — The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: ezh2 inhibitor (tazemetostat)
Lab requirements
Blood counts
ANC ≥750 cells/mm3 (≥0.75 x 10^9/L) independent of G-CSF support; Platelet count ≥75,000 cells/mm^3 (≥75 x 10^9/L) independent of transfusion support.
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Liver function
Total Bilirubin ≤1.5 x ULN or ≤3 x ULN with documented liver involvement and/or Gilbert's disease. AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; subjects with liver involvement allowed with AST and ALT ≤ 5 x ULN.
Adequate organ function as defined as: Hematologic: ANC ≥750 cells/mm3 (≥0.75 x 10^9/L) independent of G-CSF support; Platelet count ≥75,000 cells/mm^3 (≥75 x 10^9/L) independent of transfusion support. Hepatic: Total Bilirubin ≤1.5 x ULN or ≤3 x ULN with documented liver involvement and/or Gilbert's disease. AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; subjects with liver involvement allowed with AST and ALT ≤ 5 x ULN. Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Uta · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify